Screener
Vir Biotechnology, Inc. VIR Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income | 6,792 | 7,629 | 13,557 | 26,227 |
| Income (loss) before provision for income taxes | 80,259 | (110,788) | (45,266) | (231,737) |
| Provision for income taxes | (179) | (170) | (349) | (186) |
| Net income (loss) | $80,080 | $(110,958) | $(45,615) | $(231,923) |
| Net income (loss) per share, basic | $0.48 | $(0.80) | $(0.29) | $(1.68) |
| Net income (loss) per share, diluted | $0.47 | $(0.80) | $(0.29) | $(1.68) |
| Weighted-average shares outstanding, basic | 167,719,015 | 138,447,469 | 157,613,578 | 137,960,888 |
| Weighted-average shares outstanding, diluted | 168,879,127 | 138,447,469 | 157,613,578 | 137,960,888 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s business segments — net loss?
- Vir Biotechnology, Inc. (VIR) reported business segments — net loss of $80.08M in Q2 2026.
- How has Vir Biotechnology, Inc.'s business segments — net loss changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — net loss increased by 172.2% year-over-year, from -$110.96M to $80.08M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — net loss has grown at a -5.3% compound annual growth rate (CAGR), from $515.84M to -$437.99M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial performance of the segment after accounting for all revenues and operating expenses. A net loss reflects the current stage of the segment's lifecycle, typically indicating high investment in R&D relative to revenue generation.
Ask your AI about Vir Biotechnology, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude